Revenue surge clouded by profit decline, one-time restructuring charge

Delivered 23.1% YoY, within claimed range

19% PAT decline YoY matches management comment; Baddi charge ~₹96 Cr cited as one-time

Quarterly volume up 7%, YTD 4%; pricing/mix accounting for ~16% of 23% growth mathematically plausible

OPM 6.5% reported; language vague on EBITDA absolute levels; one-offs distort comparability

Delivered volume and margin growth evidence this; but QoQ PAT -32% suggests headwinds absorbed, not fully overcome

Labels plant (unprofitable, low-utilization) closed mid-Q2, charge ₹96 Cr; volumes reallocated to other plants; supply continuity maintained

Prior call emphasized productivity gains and pricing; this call acknowledges Sept cost surge, pass-through lag, and Baddi charge masking underlying operational improvement

Clarified that ~1/3 of 23% growth is volume (7% quarterly), ~2/3 is pricing and mix; focus remains on profitable growth over volume chasing

Discussed evolving plastic regulations (recycled content mandates); positioned as opportunity for innovation and margin uplift; IFCA awards won for sustainable products

Revenue growth driven by three factors: pricing, mix (higher-value products), volume (~7% quarterly, ~4% YTD). EBITDA margins 18% up on comparable basis excluding one-offs; current quarter impacted by Baddi charge and timing of cost pass-through; management expects improvement.

Recycled plastic content regulations progressive; government specifies minimum % usage. Huhtamaki well-positioned with capacity for compliant products. Sales cycle depends on customer complexity—3 months for small/regional, up to 2 years for large customers with internal approvals.

Baddi is labels plant only—unprofit. Other two plants have spare capacity. Volumes reallocated smoothly, customers served from Ambernathe & Bangalore plants, supply chain intact. Not planning similar closures; focus on efficiency, not plant optimization alone.

PAT/PBT progression: ₹117 Cr to ₹133 Cr (9M). Cost pass-through framework exists; Sept material cost surge delayed recovery to next quarter. Productivity initiatives ongoing—optimization yielding results. Can't unilaterally raise prices; depends on customer contracts and commodity cycles. On absolute terms, profit growing 13% YoY (9M), reflecting margin improvement despite quarter-level volatility.

No formal tailwinds. Growth from market share gains and pricing power. Geopolitical headwinds offset by cost pass-through. Margin recovery depends on continuation of cost-to-customer pass-through. Market is fragmented (<10% share); runway for growth. Regulatory changes (plastic mandates) create innovation opportunity.

Segment-agnostic—focus on product complexity and value. Not comparing against commodity producers. Competitors in 15-20% margin band may have different product mix (higher complexity). Huhtamaki improving from 8% to 10% trajectory (9M EBITDA growth 22 pts YoY). Innovation and customer value prop differentiate.

Management reiterates 23% growth will not repeat every quarter; focus on profitable growth over volume. Prior call stated same philosophy.

Productivity initiatives, cost pass-through timing, and mix shift toward higher-value products drive margin recovery. Sept cost surge delayed impact to Q3.

Sept raw material costs surged significantly; company has framework for pass-through but timing lag typical 1-2 months. If inflation persists and pass-through slows, margins will compress further.

Company did not quantify customer concentration, but acknowledged large customer base in FMCG/pharma sectors. Loss of major customer would impact volumes and margins.

Baddi labels plant closure with supply reallocation to Ambernathe and Bangalore plants. Risk of supply disruption or quality issues if reallocation not executed smoothly.

Huhtamaki margins (6-10% EBITDA) lag peer margins (15-20% cited by analyst). Risk that commodity product mix holds margin expansion; switching to high-value products may require customer acceptance and investment.

Recycled plastic content mandates create opportunity but require spec changes and customer approvals. Slow execution could miss market window or increase cost if regulations tighten faster than product pipeline.